Solidsoft Reply Successfully Integrates the Hellenic Medicines Verification System into the European Medicines Verification Platform
In collaboration with the Hellenic Medicines Verification Organisation (HMVO), Solidsoft Reply, a Reply Group company specialising in Microsoft Azure cloud-based enterprise solutions, has successfully integrated Greece’s Hellenic Medicines Verification System (HMVS) within the European Hub, delivering the launch on schedule. This achievement enhances Greece’s pharmaceutical landscape and protects its citizens from the growing threat of falsified medications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318137690/en/

The HMVS now operates as part of the European Medicines Verification System (EMVS), a pan-national platform designed to prevent counterfeit medicines from entering the market and reaching patients. With this launch, Greece joins a growing network of 15 other fully operational and secure National Medicine Verification System (NMVS) platforms across Europe, powered by Solidsoft Reply.
The HMVS became fully operational in February 2025, connecting approximately 10,500 pharmacies, and 150 wholesalers across Greece. Critically, it also integrates with Greece’s existing national reimbursement system. Solidsoft Reply worked closely with HMVO to ensure the system met Greece’s regulatory, technological, and operational requirements, facilitating a smooth transition to full operation.
David Eccles, Partner at Solidsoft Reply, stated: “We are delighted to have assisted HMVO in meeting their critical deadline in just six months. The successful implementation of the HMVS ensures the safety and authenticity of medicines in Greece. Kudos to everyone who contributed to this achievement.”
Ioanna Kontomanolopoulou, General Manager at HMVO, commented: “This has been achieved with the strong support of the EMVO, and the help from our colleagues from other NMVOs, and our provider Solidsoft Reply… We express our gratitude to all.”
The HMVS now operates as part of the European Medicines Verification System (EMVS), a pan-national platform designed to prevent counterfeit medicines from entering the market and reaching patients. With this launch, Greece joins a growing network of 15 other fully operational and secure National Medicine Verification System (NMVS) platforms across Europe, powered by Solidsoft Reply.
This initiative underscores Solidsoft Reply’s expanding role in healthcare systems integration across Europe, reaffirming its commitment to leveraging advanced technology to enhance patient safety, regulatory compliance, and the efficiency of pharmaceutical supply chains.
Reply
Reply [EXM, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply supports major European industrial groups in the telecom and media; industry and services; banking and insurance and public sectors in defining and developing business models enabled by the new paradigms of AI, cloud computing, digital media and the internet of things. Reply's services include: consulting, system integration and digital services. www.reply.com
Solidsoft Reply
Solidsoft Reply is a leading technology company creating award-winning solutions utilising the Microsoft Azure cloud platform. As a globally acclaimed Microsoft AI Cloud Solutions Partner, we specialise in GS1 traceability systems worldwide, crucially ensuring the authenticity, legality, and safety of our customers’ products and services. Serving non-profits, NGOs, healthcare, and the pharmaceutical industries, we deliver technology for positive social impact. Your products, safe in our hands.
Hellenic Medicines Verification Organisation (HMVO)
HMVO is a non-profit legal entity that will create, manage, operate, maintain, and oversee the “Greek Medicines Verification System” (HMVS). This initiative is in compliance with European Regulation 2016/161, which establishes detailed rules regarding the safety features displayed on the packaging of medicines for human use.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250318137690/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Laserfiche Announces 2025 Run Smarter® Award Winners18.3.2025 15:00:00 CET | Press release
Laserfiche — a leading enterprise platform that helps organizations manage their most critical content and workflows — today announced the winners of the 2025 Laserfiche Run Smarter® Awards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318932755/en/ The awards honor individuals and organizations that yield exceptional business results using Laserfiche. From a state department that revolutionized how it protects the environment to an insurance agency that leapt into action after a hurricane: The winners enhance productivity, foster innovative processes and improve lives with Laserfiche technology. “These honorees are champions of the employee and customer experience,” said Karl Chan, CEO of Laserfiche. “They are leading their industries in transforming how they work using Laserfiche. We are delighted to celebrate their remarkable achievements.” Congratulations to the 2025 Run Smarter Award winners: Angela Goerner, direct
DDC Announces Strategy to Create Bitcoin Reserves and Appoints Crypto Asset Expert Alex Yang as Strategic Advisor18.3.2025 14:14:00 CET | Press release
Bitcoin reserve to be established with up to 100 BTC injection and premium-priced placement of DDC Class A Ordinary shares at $0.50 to $1.25 per share DDC Enterprise, Ltd. (NYSEAM: DDC), (“DayDayCook,” “DDC,” or the “Company”), a leading multi-brand Asian consumer food company, today announced a transformative initiative to adopt Bitcoin as part of its treasury reserves, alongside an announcement that brings seasoned Web3 and Crypto Assets Management Expert Alex Yang to DDC as Strategic Advisor. An investor group will inject up to 100 BTC in exchange for DDC Class A Ordinary shares at a range of $0.50 to $1.25 per share, representing a 100% to 400% premium to recent trading levels. Strategic Alignment with Institutional Confidence “This partnership is a testament to the shared conviction in DDC’s future and the value of Bitcoin and potentially other crypto currencies as a strategic asset,” said Ms. Norma Chu, Chairwoman and CEO of DDC Enterprise. “This strategic decision to launch a bi
Qualcomm Increases Quarterly Cash Dividend18.3.2025 14:00:00 CET | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced that its Board of Directors has approved an increase in the Company’s quarterly cash dividend from $0.85 to $0.89 per share of common stock. This dividend increase will be effective for quarterly dividends payable after March 27, 2025, and will raise the annualized dividend payout to $3.56 per share of common stock. Cristiano Amon, President and CEO of Qualcomm Incorporated, said, “We are pleased to announce an increase in our quarterly dividend. Given our long-term growth expectations we provided at our 2024 Investor Day, we remain committed to returning capital to stockholders through a balanced capital return policy, including a baseline of anti-dilutive stock repurchases, and an annualized dividend target of low- to mid-single-digit percentage growth.” About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years
Corpay Cross-Border Grows in Europe with Launch of Luxembourg Office18.3.2025 13:30:00 CET | Press release
Expansion aims to enhance service offering for institutional clients and bolster European growth through an increased market presence Corpay, Inc.*, (NYSE: CPAY), a global leader in corporate payments, is proud to announce its entry into Luxembourg with the establishment of a new office for its Cross-Border business. As part of Corpay’s ongoing expansion in Europe, this significant move aligns with the company’s strategy to enhance its presence in key financial markets worldwide and supports its growth ambitions in the institutional investor and private funds space. “The new Luxembourg office underscores our commitment to supporting the sophisticated needs of this global client base and enables us to provide a localized solution set for our institutional clients that establish their international investment structures in Luxembourg,” says Andrew Shortreid, SVP, Global Institutional Sales, Corpay Cross-Border Solutions. “Luxembourg’s status as a major financial hub in the EMEA region, w
Novotech Partners with Kyungpook National University Hospital to Strengthen Clinical Trial Capabilities in South Korea18.3.2025 13:05:00 CET | Press release
Novotech, a global leading full-service clinical Contract Research Organization (CRO), and Acrostar, a provider of Site Management Organization (SMO) services have entered into a strategic partnership by signing a Memorandum of Understanding (MOU) with Kyungpook National University Hospital (KNUH). The partnership will support clinical trials across KNUH’s prestigious institutions including the Advanced Clinical Trials Center, the KNUH main campus, and the Chilgok KNUH in South Korea. This collaboration is a key milestone for the advanced clinical trials in South Korea, strategically aligning with the amendments to the Advanced Regenerative Bio Act. This agreement builds upon the recent inauguration of KNUH’s Advanced Clinical Trials Center opened in November last year, marking its first official partnership post-amendment of the Bio Act. The amendments to the Advanced Regenerative Bio Act expanded the scope of advanced regenerative medicine, allowing the use of investigational therapi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom